Every open market buy and sale of Pacira BioSciences, Inc. stock by its officers, directors and 10% owners over the last two years, straight from SEC Form 4 filings. Insiders are only selling over the last 12 months: $0 bought and $2.4M sold.
Buying and selling by month
open market, last 12 monthsGet an alert when PCRX insiders trade
We read every Form 4 the moment the SEC posts it and tell you when an PCRX officer, director or 10% owner buys on the open market, or sells $250K or more outside a pre-arranged plan, by email or on your phone.
Insider alerts are part of AI Pro. Start with a free account, then add AI Pro when you want the alerts.
Every PCRX insider trade
2 years · newest first| Insider | Type | Price | Held after | Filed | |||
|---|---|---|---|---|---|---|---|
| Oct 8, 2026 | Lauren RikerSenior Vice President, Finance | Sale plan | 6,000 | $36.32 | $218K | 62,284 | Oct 9Form 4 |
| Aug 17, 2026 | Jonathan SloninChief Medical Officer | Sale plan | 3,040 | $23.23 | $71K | 216,384 | Aug 18Form 4 |
| Jun 11, 2026 | Lauren RikerSenior Vice President, Finance | Sale plan | 6,115 | $23.50 | $144K | 62,284 | Jun 12Form 4 |
| Jun 4, 2026 | Kristen WilliamsChief Administrative Officer | Sale plan | 10,259 | $22.27 | $228K | 167,062 | Jun 5Form 4 |
| Apr 23, 2026 | Shawn CrossCFO | Sale plan | 12,941 | $25.16 | $326K | 105,341 | Apr 24Form 4 |
| Apr 22, 2026 | Shawn CrossCFO | Sale plan | 12,059 | $25.09 | $303K | 105,341 | Apr 22Form 4 |
| Mar 17, 2026 | Mark FroimsonDirector | Sale | 500 | $21.81 | $11K | 20,136 | Mar 19Form 4 |
| Mar 17, 2026 | Jonathan SloninChief Medical Officer | Sale plan | 3,261 | $22.82 | $74K | 223,640 | Mar 19Form 4 |
| Feb 2, 2026 | Kristen WilliamsChief Administrative Officer | Sale plan | 13,137 | $20.53 | $270K | 131,303 | Feb 3Form 4 |
| Feb 2, 2026 | Lauren RikerSenior Vice President, Finance | Sale plan | 4,000 | $20.81 | $83K | 52,313 | Feb 3Form 4 |
| Jan 5, 2026 | Lauren RikerSenior Vice President, Finance | Sale plan | 1,416 | $24.24 | $34K | 59,064 | Jan 6Form 4 |
| Dec 10, 2025 | Shawn CrossCFO | Sale plan | 25,000 | $25.07 | $627K | 56,250 | Dec 11Form 4 |
| Nov 17, 2025 | Jonathan SloninChief Medical Officer | Sale plan | 3,960 | $24.09 | $95K | 178,367 | Nov 19Form 4 |
| Nov 10, 2025 | Shawn CrossCFO | Sale plan | 12,060 | $22.09 | $266K | 56,250 | Nov 13Form 4 |
| Sep 4, 2025 | Abraham CeesayDirector | Sale plan | 2,354 | $27.19 | $64K | 9,039 | Sep 8Form 4 |
PCRX insider trading FAQ
Are PCRX insiders buying or selling?
Insiders are only selling over the last 12 months. 0 insiders bought $0 of PCRX on the open market in 0 trades, and 5 sold $2.4M in 12 trades, 100% of that under pre-arranged trading plans.
When did an PCRX insider last buy shares?
There has been no open market insider purchase of PCRX in the last two years.
When did an PCRX insider last sell shares?
Lauren Riker (Senior Vice President, Finance) sold 6,000 shares for $218K on Oct 8, 2026, under a pre-arranged trading plan.
What is a Form 4?
Company officers, directors and owners of more than 10% of the shares must report trades in the company's stock to the SEC on Form 4 within two business days. This page shows open market buys and sales only. Option exercises, stock awards, gifts and shares withheld for taxes are left out, since they are not decisions to buy or sell.
Why do insider sales matter less than buys?
Insiders sell for many reasons, such as taxes, diversification or a home purchase, and many sales are scheduled months ahead under a 10b5-1 trading plan. They buy on the open market mostly when they expect the shares to rise, which is why buying, and especially several insiders buying together, gets more attention.
For informational and educational purposes only. Not investment advice, and not a recommendation to buy or sell any security. Trades come from SEC Form 4 filings as reported by the insiders. Insiders have two business days to report, so a trade can be a few days old when it appears. See all insider cluster buys.
From SEC Form 4 filings · Not investment advice
